Karyopharm Therapeutics 2024 HC Wainwright Conference Presentation

Karyopharm Therapeutics presented at the HC Wainwright 26th Annual Global Investment Conference in September 2024, discussing selinexor (XPOVIO) development and commercialization. The presentation covers the company's refinancing transactions, 2024 financial guidance, and clinical development plans for selinexor across multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma.